DRR168555
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.500
- HEDGEHOG_SIGNALING+0.480
- MYOGENESIS+0.480
- TNFA_SIGNALING_VIA_NFKB+0.420
- IL6_JAK_STAT3_SIGNALING+0.350
- ALLOGRAFT_REJECTION+0.340
- ANGIOGENESIS+0.340
- APICAL_JUNCTION+0.330
- INFLAMMATORY_RESPONSE+0.320
- WNT_BETA_CATENIN_SIGNALING+0.290
Top 10 suppressed
- PROTEIN_SECRETION-0.540
- MYC_TARGETS_V1-0.490
- OXIDATIVE_PHOSPHORYLATION-0.470
- E2F_TARGETS-0.430
- MTORC1_SIGNALING-0.350
- G2M_CHECKPOINT-0.330
- FATTY_ACID_METABOLISM-0.290
- MYC_TARGETS_V2-0.270
- GLYCOLYSIS-0.260
- PEROXISOME-0.260
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | R52 | — | — | 0.931 |
| 2 | TCGA-AC-A3W6-01A-12R-A22K-07 | — | A | 0.927 |
| 3 | SRR23303731 | — | — | 0.919 |
| 4 | SRR35579837 | — | D | 0.914 |
| 5 | AUR-AER2-TTM3-A-1-1-R-A742-41 | — | D | 0.910 |
| 6 | TCGA-C8-A8HR-01A-11R-A36F-07 | — | A | 0.909 |
| 7 | TCGA-XX-A899-01A-11R-A36F-07 | — | A | 0.901 |
| 8 | TCGA-78-8648-01A-11R-2403-07 | — | cohortMD2 | 0.898 |
| 9 | f22cfa82-a346-4fed-bc81-21a29bf990ee | — | — | 0.893 |
| 10 | TCGA-LL-A440-01A-11R-A24H-07 | — | A | 0.891 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 30 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.500 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.480 | Inavolisib | — uncovered |
| MYOGENESIS | 0.480 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.420 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.350 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.340 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.340 | Remibrutinib | — uncovered |
| APICAL_JUNCTION | 0.330 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.320 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.290 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.260 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.250 | Inavolisib | — uncovered |
| COAGULATION | 0.240 | Binimetinib | — uncovered |
| COMPLEMENT | 0.240 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.240 | Cobimetinib | — uncovered |
| HYPOXIA | 0.230 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.220 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.200 | Remibrutinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.180 | Idelalisib | — uncovered |
| APOPTOSIS | 0.150 | Idelalisib | — uncovered |